Purpose
Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRP-R) are expressed in prostate cancer and can be targeted with radiolabeled inhibitors and antagonists. Their performances for the initial characterization of prostatic tumors have been barely evaluated but never compared. We aimed to gather comparative preclinical data of the role of PSMA and GRP-R targeting in prostate cancer.
Procedures
We retrospectively studied 20 frozen prostatectomy samples with various metastatic risks of the D’Amico classification. Tissue samples were investigated by tissular microimaging using the radiolabeled PSMA inhibitor
111
In-PSMA-617 and the radiolabeled GRP-R antagonist
111
In-RM2. Bindings of the two radiopharmaceuticals were compared to histology and clinico-biological data (Gleason score, PSA values, metastatic risks).
Results
Binding of
111
In-PSMA-617 was high whatever the metastatic risk (
p
= 0.665), Gleason score (
p
= 0.555), or PSA value (
p
= 0.404) while
111
In-RM2 exhibited a significantly higher binding in the low metastatic risk group (
p
= 0.046), in the low PSA value group (
p
= 0.001), and in samples with Gleason 6 score (
p
= 0.006).
Conclusion
PSMA and GRP-R based imaging might have complementary performances for the initial characterization of prostatic tumors. Prospective clinical studies comparing the two tracers in this setting are needed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.